Plus Therapeutics, Inc. (PSTV) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PSTV Revenue Growth
Revenue Breakdown (FY 2022)
PSTV's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
PSTV Revenue Analysis (2014–2025)
As of May 8, 2026, Plus Therapeutics, Inc. (PSTV) generated trailing twelve-month (TTM) revenue of $5.2 million, reflecting slight decline in growth of -3.2% year-over-year. The most recent quarter (Q4 2025) recorded $1.4 million in revenue, down 2.1% sequentially.
Looking at the longer-term picture, PSTV's 5-year compound annual growth rate (CAGR) stands at +76.7%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $11.7 million in 2015.
Revenue diversification analysis shows PSTV's business is primarily driven by Grant (100%). With over half of revenue concentrated in Grant, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NRXP, AGEN (+10.4% YoY), and CLDX (-78.6% YoY), PSTV has underperformed the peer group in terms of revenue growth. Compare PSTV vs NRXP →
PSTV Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PSTVCurrent | $5M | -3.2% | +76.7% | -293.5% | |
 NRXP | $1M | - | - | -1324.4% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
 IART | $1.6B | +1.2% | +3.6% | 4.2% | |
 ACTG | $285M | -3.3% | +57.1% | 2.2% |
PSTV Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.2M | -10.5% | $4.8M | 91.5% | $-15,298,000 | -293.5% |
| 2024 | $5.8M | +18.5% | $5.0M | 85.4% | $-14,695,000 | -252.3% |
| 2023 | $4.9M | +2093.3% | $-4,777,000 | -97.2% | $-13,321,000 | -271.1% |
| 2022 | $224K | - | $-488,000 | -217.9% | $-19,712,000 | -8800.0% |
| 2021 | $0 | -100.0% | $-66,000 | - | $-12,492,000 | - |
| 2020 | $303K | -95.7% | $-2,397,000 | -791.1% | $-9,584,000 | -3163.0% |
| 2019 | $7.0M | +134.6% | $7.0M | 100.0% | $-3,657,000 | -52.3% |
| 2018 | $3.0M | -53.5% | $1.8M | 61.5% | $-8,762,000 | -293.7% |
| 2017 | $6.4M | -43.7% | $5.1M | 79.4% | $-20,683,000 | -322.6% |
| 2016 | $11.4M | -2.4% | $8.7M | 76.1% | $-19,706,000 | -173.2% |
See PSTV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PSTV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PSTV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPSTV — Frequently Asked Questions
Quick answers to the most common questions about buying PSTV stock.
Is PSTV's revenue growth accelerating or slowing?
PSTV revenue growth slowed to -3.2%, below the 5-year CAGR of +76.7%. TTM revenue is $5M. The deceleration marks a shift from historical growth rates.
What is PSTV's long-term revenue growth rate?
Plus Therapeutics, Inc.'s 5-year revenue CAGR of +76.7% reflects the variable expansion pattern. Current YoY growth of -3.2% is near this long-term average.
How is PSTV's revenue distributed by segment?
PSTV reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.